Table 2.
Changes in modifiable cardiovascular risk factors and Framingham score at the three time points of the study in the 81 included patients.
| Laboratory data | Before starting ARV | At the time of the coronary eventa | Last observationb |
c
P value (baseline to coronary event) |
d
P value (event to present) |
|---|---|---|---|---|---|
| CD4, cell/µL (median [IQR]) | 224 (89, 422) | 497 (384, 776) | 559 (375, 767) | 0.000 | 0.201 |
| HIV-RNA, log (median [IQR]) | 4.6 (3.6, 5.3) | 1.8 (1.4, 2.7) | 1.4 (1.3, 1.7) | 0.000 | 0.000 |
| Serum total cholesterol, mg/dL (median [IQR]) | 185 (154, 213) | 182 (152, 230) | 174 (147, 205) | 0.402 | 0.025 |
| Serum HDL-cholesterol, mg/dL (median [IQR]) | 41 (30, 43) | 42 (35, 52) | 45 (33, 53) | 0.155 | 0.974 |
| Serum LDL-cholesterol, mg/dL (median [IQR]) | 102 (97, 189) | 104 (98, 194) | 95 (86, 124) | 0.305 | 0.004 |
| CT/HDL-cholesterol ratio mmol/L | 4.3 (3.8, 5.6) | 4.1 (3.1, 5.8) | 4 (3.1, 5.2) | 0.110 | 0.339 |
| Serum triglycerides, mg/dL (median [IQR]) | 151 (106, 204) | 168 (106, 248) | 142 (95, 204) | 0.778 | 0.111 |
| Glycemia, mg/dL (median [IQR]) | 90 (85, 103) | 97 (88, 108) | 95 (88, 108) | 0.140 | 0.299 |
| Glomerular filtration rate, mL/min (median [IQR]) | 60 (60, 60) | 60 (60, 60) | 60 (60, 60) | 0.317 | 0.317 |
| Serum total cholesterol >200 mg/dL (n, %) | 18 (49) | 29 (45) | 25 (35.2) | 0.265 | 0.738 |
| Serum HDL-cholesterol <40 mg/dL (n, %) | 73 (90) | 21 (44) | 25 (39.7) | 0.001 | 1.000 |
| Serum LDL-cholesterol >100 mg/dL (n, %) | 7 (46) | 17 (45) | 25 (41%) | — | 0.103 |
| Serum triglycerides >200 mg/dL (n, %) | 15 (41) | 30 (37) | 26 (32.1) | 0.022 | 0.238 |
| Serum triglycerides >500 mg/dL (n, %) | 1 (2.7) | 4 (6.3) | 3 (4.1) | 0.118 | 0.193 |
| Glycemia >110 mg/dL (n, %) | 5 (15) | 15 (23) | 17 (24.3) | 0.001 | 0.52 |
| Framingham <10% (low) (n, %) | 2 (50) | 3 (25) | 11 (44) | — | — |
| Framingham 10%–20% (moderate) (n, %) | 2 (50) | 8 (67) | 8 (32) | — | — |
| Framingham >20% (high) (n, %) | — | 1 (8) | 6 (24) | — | — |
aMedian time (IQR) from starting antiretroviral treatment until the coronary event: 8 (5; 12) years; bmedian time (IQR) from the coronary event until the last follow-up visit (June 2011): 7 (4; 11) years.
c P value denotes change from baseline to the time of the coronary event; d P value denotes change from the coronary event to the last follow-up visit.
CT: total cholesterol; HDL: high-density lipoprotein; LDL: low-density lipoprotein.